polymyositis

Polymyositis is a chronic inflammatory disease characterized by symmetrical myopathy and muscle degeneration. It is characterized by progressive weakness of skeletal muscles, especially proximal groups such as the shoulder girdle and hip muscles. Classification of polymyositis includes idiopathic polymyositis, dermatomyositis, vasculitis-associated and other syndromes. The etiologic factors of polymyositis continue to be studied, but a combination of genetic predispositions and environmental triggers play a key role in the pathogenesis of the disease.

History of the disease and interesting historical facts

Polymyositis as a disease was first described in medical literature in the early 19th century. In 1891, Italian physician T. R. Vincentini presented a case of a patient with characteristic muscle weakness, which initiated a more detailed study of this condition. In the early 20th century, researchers began to distinguish polymyositis from other myopathies, noting its specific clinical manifestations and laboratory characteristics. One of the turning points in the study of polymyositis occurred in 1975, when scientists identified autoimmune mechanisms associated with this disease. Thanks to modern molecular biology and genetics, markers have been identified that allow better diagnosis and understanding of the various forms of polymyositis.

Epidemiology

According to various epidemiological studies, polymyositis occurs with a frequency of 1-10 cases per 100,000 population. The disease is diagnosed more often in women than in men, with a ratio of approximately 2:1. The age of onset of symptoms varies from 30 to 60 years, but cases of the disease in childhood and old age are possible. The prevalence of polymyositis may be higher in some communities, especially in populations with a high predisposition to autoimmune diseases. It is important to consider the influence of ethnic and geographic factors in understanding the incidence, which highlights the need for further research in this area.

Genetic predisposition to this disease

Genetic predisposition to polymyositis is studied through the analysis of various mutations and polymorphisms in genes associated with the immune system. One of the most studied genes is HLA-DRB1, associated with an increased risk of developing autoimmune diseases. Other genes involved include TNF-α, INF-γ and IL-6, which play a key role in inflammatory processes. Research shows that the presence of certain genetic markers may indicate an increased risk of developing the disease, which opens up new horizons for understanding the pathogenesis of polymyositis and the possibility of an individualized approach to treatment.

Risk factors for the development of this disease

Risk factors for polymyositis can be divided into the following categories:

• Physical factors: The presence of injuries, excessive physical activity, high temperatures and their sudden changes can contribute to the development of myositis.
• Chemical factors: Exposure of the body to toxic compounds, such as certain drugs (eg, statins) and organic solvents, may be a trigger for the development of the disease.
• Infectious agents: Some viral infections, such as the Epstein-Barr virus, may contribute to the development of polymyositis in people with weakened immune systems.
• Autoimmune diseases: A history of other autoimmune diseases significantly increases the risk of developing polymyositis.

These factors highlight the importance of early detection and diagnosis of polymyositis to improve the prognosis of the disease.

Diagnosis of this disease

Diagnosis of polymyositis is based on clinical, laboratory and instrumental methods. The main symptoms are:

• Progressive weakness in the proximal muscles;
• Muscle pain;
• Limitation of mobility.

Laboratory tests include:

• Determination of the level of creatine kinase (CK), which is often elevated in muscle damage;
• Antisteroid antibodies (eg, Jo-1), characteristic of polymyositis;
• Other immunological markers.

Radiological examinations such as MRI can visualize changes in muscle tissue. Other diagnostics include electromyography and muscle biopsy, which can confirm inflammatory changes. Differential diagnosis should include other myopathies and diseases associated with muscle weakness.

Treatment

Treatment of polymyositis involves a comprehensive approach aimed at reducing inflammation and restoring muscle function. Common treatments include:

• Pharmacological treatment aimed at suppressing the immune response;
• Physiotherapy to improve muscle tone and strength;
• Surgical treatment in rare cases when surgical intervention is required.

Pharmacological treatment usually includes corticosteroids, such as prednisolone, which reduce inflammation. In addition, immunosuppressants, such as methotrexate or azathioprine, may be used. In some cases, biologic therapy is used.

List of medications used to treat this disease

• Prednisolone;
• Methotrexate;
• Azathioprine;
• Ritanoximab;
• Hydroxychloroquine.

Each of these drugs requires individual evaluation and monitoring depending on the clinical situation.

Disease monitoring

Monitoring of polymyositis involves regular observation of the patient's condition and assessment of the response to therapy. Monitoring steps may include:

• Regular tests for creatine kinase levels;
• Assessment of muscle strength and function;
• Monitoring for side effects from treatment.

The prognosis of polymyositis varies depending on timely diagnosis and treatment. Complications may include significant loss of muscle function, which can lead to disability.

Age-related features of the disease

Polymyositis can manifest itself in different age groups, but the pilot period of its symptoms development is most often observed in people of the middle group (30-60 years). In children, polymyositis can manifest itself in the form of dermatomyositis, accompanied by skin changes and myopathy. In older people, the disease can proceed with less pronounced symptoms, but is often accompanied by concomitant diseases, which complicates treatment and monitoring.

Questions and Answers

• What are the symptoms of polymyositis? The main symptoms include progressive weakness of the proximal muscles, muscle pain and limitation of mobility.
• What is the general treatment plan for polymyositis? Treatment includes corticosteroids, immunosuppressants, and physical therapy to restore muscle function.
• Is it possible to completely cure polymyositis? Polymyositis is a chronic disease, but with early detection and adequate treatment, improvement is possible.
• How is polymyositis diagnosed? Diagnosis is based on clinical manifestations, laboratory tests and instrumental studies such as MRI.
• What is the prognosis for patients with polymyositis? Prognosis depends on the timing of treatment, but many patients can achieve improved quality of life with adequate monitoring and therapy.

This information provides a comprehensive overview of polymyositis, its characteristics, diagnosis and treatment, promoting a better understanding of this complex disease.